137 related articles for article (PubMed ID: 36639903)
21. Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis.
Elshafei MN; El-Bardissy A; Khalil A; Danjuma M; Mubasher M; Abubeker IY; Mohamed MFH
Eur J Clin Invest; 2021 Sep; 51(9):e13645. PubMed ID: 34185313
[TBL] [Abstract][Full Text] [Related]
22. Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California.
Young-Wolff KC; Slama N; Alexeeff SE; Sakoda LC; Fogelberg R; Myers LC; Campbell CI; Adams AS; Prochaska JJ
Nicotine Tob Res; 2023 Jan; 25(2):211-220. PubMed ID: 35368066
[TBL] [Abstract][Full Text] [Related]
23. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
Tardif JC; Bouabdallaoui N; L'Allier PL; Gaudet D; Shah B; Pillinger MH; Lopez-Sendon J; da Luz P; Verret L; Audet S; Dupuis J; Denault A; Pelletier M; Tessier PA; Samson S; Fortin D; Tardif JD; Busseuil D; Goulet E; Lacoste C; Dubois A; Joshi AY; Waters DD; Hsue P; Lepor NE; Lesage F; Sainturet N; Roy-Clavel E; Bassevitch Z; Orfanos A; Stamatescu G; Grégoire JC; Busque L; Lavallée C; Hétu PO; Paquette JS; Deftereos SG; Levesque S; Cossette M; Nozza A; Chabot-Blanchet M; Dubé MP; Guertin MC; Boivin G;
Lancet Respir Med; 2021 Aug; 9(8):924-932. PubMed ID: 34051877
[TBL] [Abstract][Full Text] [Related]
24. Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis.
De-Miguel-Balsa E; Estevan-Ortega R; Sempere-Selva MT; Latour-Pérez J; Baeza-Román A; Moya-Martinez A; Ramos-Rincon JM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7151-7161. PubMed ID: 34859881
[TBL] [Abstract][Full Text] [Related]
25. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
Eikelboom JW; Jolly SS; Belley-Cote EP; Whitlock RP; Rangarajan S; Xu L; Heenan L; Bangdiwala SI; Tarhuni WM; Hassany M; Kontsevaya A; Harper W; Sharma SK; Lopez-Jaramillo P; Dans AL; Palileo-Villanueva LM; Avezum A; Pais P; Xavier D; Felix C; Yusufali A; Lopes RD; Berwanger O; Ali Z; Wasserman S; Anand SS; Bosch J; Choudhri S; Farkouh ME; Loeb M; Yusuf S
Lancet Respir Med; 2022 Dec; 10(12):1160-1168. PubMed ID: 36228639
[TBL] [Abstract][Full Text] [Related]
26. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
27. Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19).
Mareev VY; Orlova YA; Plisuk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malahov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov МA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina EM; Sinitsyn VE; Mareev YV; Shatokhina EA; Begrambekova YL; Kamalov AA
Kardiologiia; 2022 Dec; 62(12):11-22. PubMed ID: 36636972
[TBL] [Abstract][Full Text] [Related]
28. Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial.
Shah T; McCarthy M; Nasir I; Archer H; Ragheb E; Kluger J; Kashyap N; Paredes C; Patel P; Lu J; Kandel P; Song C; Khan M; Ul Haq F; Ahmad R; Howes C; Cambi B; Lancaster G; Cleman M; Dela Cruz CS; Parise H; Lansky A
Contemp Clin Trials; 2021 Nov; 110():106547. PubMed ID: 34461322
[TBL] [Abstract][Full Text] [Related]
29. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
30. Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study.
Visos-Varela I; Zapata-Cachafeiro M; Pintos-Rodríguez S; Bugarín-González R; González-Barcala FJ; Herdeiro MT; Piñeiro-Lamas M; Figueiras A; Salgado-Barreira Á
J Med Virol; 2023 Jul; 95(7):e28971. PubMed ID: 37486310
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 severity and age increase the odds of delirium in hospitalized adults with confirmed SARS-CoV-2 infection: a cohort study.
LaHue SC; Escueta DP; Guterman EL; Patel K; Harrison KL; Boscardin WJ; Douglas VC; Newman JC
BMC Psychiatry; 2022 Feb; 22(1):151. PubMed ID: 35227231
[TBL] [Abstract][Full Text] [Related]
32. Incidence and course of COVID-19 hospitalizations among patients with familial Mediterranean fever.
Kharouf F; Ishay Y; Kenig A; Bitan M; Ben-Chetrit E
Rheumatology (Oxford); 2021 Oct; 60(SI):SI85-SI89. PubMed ID: 34293118
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia.
Abolfotouh MA; Musattat A; Alanazi M; Alghnam S; Bosaeed M
BMC Infect Dis; 2022 Dec; 22(1):950. PubMed ID: 36526994
[TBL] [Abstract][Full Text] [Related]
34. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of patients affecting the duration of positivity at SARS-CoV-2: a cohort analysis of the first wave of epidemic in Italy.
Milani L; Cigliano F; Catalano A; Macciotta A; Viola M; Caramello V; Costa G; Ricceri F; Sacerdote C
Epidemiol Prev; 2021; 45(6):533-542. PubMed ID: 35001598
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 severity appears to be reduced in spring/summer.
Sposato B; Serafini A; Simoncini E; Croci L; Guidoni C; Scalese M; Baratta P; Cresti A; Lacerenza LG; Lena F; Nencioni C; Spargi G; Perrella A;
Epidemiol Prev; 2023; 47(1-2):34-46. PubMed ID: 36971236
[TBL] [Abstract][Full Text] [Related]
37. Asthma as a risk factor for hospitalization in children with COVID-19: A nested case-control study.
Gaietto K; Freeman MC; DiCicco LA; Rauenswinter S; Squire JR; Aldewereld Z; Iagnemma J; Campfield BT; Wolfson D; Kazmerski TM; Forno E
Pediatr Allergy Immunol; 2022 Jan; 33(1):e13696. PubMed ID: 34775650
[TBL] [Abstract][Full Text] [Related]
38. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
39. Colchicine use in patients with COVID-19: A systematic review and meta-analysis.
Chiu L; Lo CH; Shen M; Chiu N; Aggarwal R; Lee J; Choi YG; Lam H; Prsic EH; Chow R; Shin HJ
PLoS One; 2021; 16(12):e0261358. PubMed ID: 34962939
[TBL] [Abstract][Full Text] [Related]
40. Multimorbidity and SARS-CoV-2-Related Outcomes: Analysis of a Cohort of Italian Patients.
Catalano A; Dansero L; Gilcrease W; Macciotta A; Saugo C; Manfredi L; Gnavi R; Strippoli E; Zengarini N; Caramello V; Costa G; Sacerdote C; Ricceri F
JMIR Public Health Surveill; 2023 Feb; 9():e41404. PubMed ID: 36626821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
